CD274 and diffuse large B-cell lymphoma: Based on recent studies suggesting that MYC upregulates immune checkpoint pathways such as programmed death-ligand 1 (PD-L1) [42], immunotherapy can be added to CD5+ DLBCL patients overexpressing MYC.